Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AG 85

Known as: AG-85, AG85 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
The mycolyl transferase antigen 85 complex is a major secreted protein family from mycobacterial culture filtrate, demonstrating… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
Interleukin‐1β (IL‐1β) represents one of the most important mediators of inflammation and host responses to infection… Expand
Highly Cited
2008
Highly Cited
2008
BackgroundAlthough BCG vaccination is recommended in most countries of the world, little is known of the persistence of BCG… Expand
  • table 1
  • figure 3
  • figure 4
2006
2006
DNA vaccines encoding the 32 000 MW mycolyl‐transferase Ag85A and the 40 000 MW phosphate‐binding protein PstS‐3 can elicit… Expand
Review
2002
Review
2002
  • A. Mustafa
  • Molecular immunology
  • 2002
  • Corpus ID: 436369
Tuberculosis (TB) is a major infectious disease problem with one-third of the world population infected, 8 million people… Expand
2001
2001
ABSTRACT Laboratory diagnosis of tuberculosis is often difficult. Immunodetection of circulating Mycobacterium… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2000
Highly Cited
2000
CD8+ T cells are thought to play an important role in protective immunity to tuberculosis. Although several nonprotein ligands… Expand
  • table I
  • figure 2
  • figure 1
  • figure 3
  • figure 4
2000
2000
There is increasing evidence to implicate a role for CD8(+) T cells in protective immunity against tuberculosis. Recombinant… Expand
1999
1999
ABSTRACT Antigen 85 (Ag85) complex proteins are major secretory products ofMycobacterium tuberculosis and induce strong cellular… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
1997
Highly Cited
1997
Few studies have analysed the antibody response during intravesical BCG immunotherapy for superficial bladder cancer. We have… Expand